VBI Vaccines Inc.
VBI Vaccines is driven by immunology in the pursuit of powerful prevention and treatment of disease. The company focuses on developing vaccine and immunotherapeutic candidates to address significant unmet public health and medical needs, leveraging the science of virus-like particles to elicit natural and potent immune responses. The company has a strong leadership team with extensive experience in vaccine development, public health, and biopharmaceuticals, including experts like Dr. Pierre Van Damme, Dr. John D. Grabenstein, Dr. Damian Braga, Dr. Adam Finn, Dr. Peter Patriarca, Dr. Michel De Wilde, Dr. Stefan Thoelen, Dr. Nadia Tornieporth, Dr. Michael Decker, Dr. Michael Lim, Dr. Allen Waziri, Dr. Patrick Yung Wen, Dr. Robert Pass, and Dr. Stanley Plotkin. The company is actively involved in clinical trials, research collaborations, and has a pipeline of vaccine candidates targeting hepatitis B, glioblastoma, medulloblastoma, cytomegalovirus, and other infectious diseases, as well as COVID-19 and other coronavirus variants.
Industries
Nr. of Employees
small (1-50)
VBI Vaccines Inc.
Cambridge, Massachusetts, United States, North America
Products
Recombinant multi-antigen hepatitis B vaccine (previously commercialized)
A recombinant, multi-antigen hepatitis B vaccine formulation that was previously commercially available and supported adult immunization programs prior to discontinuation of operations.
Enveloped VLP vaccine platform and candidate portfolio
An enveloped virus-like particle vaccine platform used for discovery and development of prophylactic and therapeutic vaccine candidates, supporting preclinical and early clinical programs.
mRNA-launched enveloped VLP technology program (preclinical)
A preclinical technology program that combines mRNA delivery with enveloped particle presentation to enhance immunogenicity relative to antigen expression alone.
Multivalent/pan-coronavirus vaccine candidate (early clinical)
A multivalent vaccine candidate designed to induce broad and durable neutralizing responses against multiple coronavirus variants, supported by preclinical challenge data and early clinical evaluation.
Oncology immunotherapy vaccine candidate (early-phase clinical)
An oncology vaccine candidate evaluated in early-phase and randomized controlled studies for recurrent glioblastoma with integrated biomarker analyses and tumor response assessments.
Peptide-based vaccine platform and influenza-focused candidates (early-stage)
A peptide-based vaccine platform and early-stage infectious disease candidates advanced toward clinical development, intended to enable antigen-focused immunity against respiratory pathogens.
Recombinant multi-antigen hepatitis B vaccine (previously commercialized)
A recombinant, multi-antigen hepatitis B vaccine formulation that was previously commercially available and supported adult immunization programs prior to discontinuation of operations.
Enveloped VLP vaccine platform and candidate portfolio
An enveloped virus-like particle vaccine platform used for discovery and development of prophylactic and therapeutic vaccine candidates, supporting preclinical and early clinical programs.
mRNA-launched enveloped VLP technology program (preclinical)
A preclinical technology program that combines mRNA delivery with enveloped particle presentation to enhance immunogenicity relative to antigen expression alone.
Multivalent/pan-coronavirus vaccine candidate (early clinical)
A multivalent vaccine candidate designed to induce broad and durable neutralizing responses against multiple coronavirus variants, supported by preclinical challenge data and early clinical evaluation.
Oncology immunotherapy vaccine candidate (early-phase clinical)
An oncology vaccine candidate evaluated in early-phase and randomized controlled studies for recurrent glioblastoma with integrated biomarker analyses and tumor response assessments.
Peptide-based vaccine platform and influenza-focused candidates (early-stage)
A peptide-based vaccine platform and early-stage infectious disease candidates advanced toward clinical development, intended to enable antigen-focused immunity against respiratory pathogens.
Services
Collaborative research and development partnerships
Collaborations with external organizations for vaccine research, development and commercialization, including government and non-profit funded programs.
Clinical development and trial collaboration
Support for design and execution of clinical studies for prophylactic and therapeutic vaccine programs, including protocol development, adaptive early-phase designs, randomized controlled trials, immunomonitoring and endpoint assessment.
Advisory board facilitation and external expert engagement
Facilitation of advisory board services and engagement with external scientific, clinical and commercial experts across vaccinology, regulatory affairs, pharmacovigilance, manufacturing, biostatistics and therapeutic areas to inform development strategy and regulatory planning.
Scientific conference presentations and data dissemination
Preparation and delivery of posters, abstracts and oral presentations to scientific and medical conferences to share preclinical and clinical data.
Strategic government and public-funded program collaborations
Management and execution of collaborations with government agencies and public funders to accelerate technology-platform development and candidate advancement.
Manufacturing asset licensing and contract manufacturing arrangements
Structuring of transactions for sale or licensing of manufacturing capabilities and related IP, and establishing manufacturing partnerships for clinical and commercial supply.
Collaborative research and development partnerships
Collaborations with external organizations for vaccine research, development and commercialization, including government and non-profit funded programs.
Clinical development and trial collaboration
Support for design and execution of clinical studies for prophylactic and therapeutic vaccine programs, including protocol development, adaptive early-phase designs, randomized controlled trials, immunomonitoring and endpoint assessment.
Advisory board facilitation and external expert engagement
Facilitation of advisory board services and engagement with external scientific, clinical and commercial experts across vaccinology, regulatory affairs, pharmacovigilance, manufacturing, biostatistics and therapeutic areas to inform development strategy and regulatory planning.
Scientific conference presentations and data dissemination
Preparation and delivery of posters, abstracts and oral presentations to scientific and medical conferences to share preclinical and clinical data.
Strategic government and public-funded program collaborations
Management and execution of collaborations with government agencies and public funders to accelerate technology-platform development and candidate advancement.
Manufacturing asset licensing and contract manufacturing arrangements
Structuring of transactions for sale or licensing of manufacturing capabilities and related IP, and establishing manufacturing partnerships for clinical and commercial supply.
Expertise Areas
- Enveloped VLP vaccine platform development
- mRNA-launched particle platform development
- Peptide-based vaccine platform development
- GMP bioprocessing and scale-up for biologics
Key Technologies
- Enveloped virus-like particle (VLP) platforms
- mRNA-based antigen expression and mRNA-launched particle approaches
- Peptide-based vaccine platforms
- Recombinant protein antigen production